The crux of this breakthrough lies in understanding the role of glucocorticoid receptors within tumour cells. These receptors respond to stress hormones in the body — glucocorticoids — and are pivotal in signaling the cancer cells to enter a state of minimal division, essentially placing them in a dormancy that protects them from many cancer drugs. This biological response to hormonal stress is particularly relevant in certain cancers, including specific forms of lung cancer, where stress hormones can trigger this protective, inactive state. Disrupting this process has been a critical challenge, as glucocorticoid receptors are ubiquitously present in healthy cells throughout the body and play vital roles in regulating inflammation and immune responses.

Eliminating these receptors systemically is not a viable solution due to their essential physiological functions; such a broad approach could result in devastating side effects, undermining the patient’s health further. To circumvent this problem, researchers have ingeniously designed a system that targets only the glucocorticoid receptors of tumour cells, leaving healthy tissue unharmed. This precision is achieved by employing a light-controlled mechanism that confines therapeutic activity strictly to the tumour site. The research team harnessed existing medical light technology to create an adaptable and localised therapeutic strategy, which they believe has imminent clinical potential.

At the heart of the new strategy is the use of an intrinsic cellular recycling process known as the ubiquitin-proteasome system. This natural pathway maintains cellular health by tagging damaged or unwanted proteins with a small molecule label, ubiquitin, marking them for degradation and recycling. Recognizing that this system could be co-opted to selectively degrade glucocorticoid receptors, the researchers devised a synthetic molecular “switch.” This switch comprises three main components: a subunit engineered to bind the receptor; a flexible connector that modulates the spatial relationship between molecules; and a subunit that recruits the ubiquitin-tagging enzyme responsible for initiating degradation.

The true innovation lies within the connector molecule’s design, which is photosensitive. Under normal, ambient light conditions, this linker maintains an extended conformation that correctly orients the enzyme near the receptor, promoting effective tagging and subsequent receptor breakdown. However, when exposed to light of a specific wavelength, the connector undergoes a conformational change — it bends or kinks — disrupting the enzyme’s proximity to the receptor and halting the tagging process. This reversible, light-controlled modulation creates an elegant on-off switch for receptor degradation that can be precisely and non-invasively controlled.

Collaborative efforts across multiple research disciplines at ETH Zurich made this advancement possible. Organic synthesis experts headed by Professor Erick Carreira synthesized a collection of potential linker molecules, experimenting with varied chemical structures to optimize photosensitivity and molecular flexibility. Two linker variants demonstrated ideal performance in laboratory tests, effectively switching receptor degradation on or off in response to specific light cues. This level of molecular control enables unprecedented precision in controlling the receptor fate directly within living cells.

The implications of such technology in cancer treatment are profound. The envisioned clinical protocol involves injecting the photoswitchable system into the tumour, thereby facilitating continuous receptor degradation within the cancerous tissue. Thereafter, a controlled application of light — carefully calibrated to penetrate just enough tissue but not beyond — would deactivate any switches that escape into healthy surrounding areas. This strategy effectively creates an “optical barrier,” localizing receptor destruction to the tumour core. This targeted approach not only enhances therapeutic efficacy but also drastically reduces the risk of side effects often associated with systemic treatments.

Proof of principle has already been established in vitro, with lung cancer cell cultures providing a fertile ground for demonstration. Researchers observed a rapid and pronounced degradation of glucocorticoid receptors upon treatment with the light-sensitive switch system. This receptor loss corresponded with a molecular awakening of the cancer cells from their dormant state, evidenced by marked changes in gene expression profiles. Such findings underscore the potential of the system to undermine a critical resistance mechanism in tumours and sensitize them to subsequent therapeutic interventions.

While promising, the technology faces practical challenges related to light delivery and tissue penetration. Visible light, as used in the current experiments, only penetrates a few millimeters into biological tissue, necessitating the proximity of the light source to the tumour. In accessible cancers such as lung carcinoma, this limitation can be addressed with endoscopic tools, facilitating illumination at close range without invasive surgery. For deeper-seated tumours, researchers are actively working to modify the system so it responds to longer wavelengths such as near-infrared light, which safely penetrates deeper into tissue and may allow for the treatment of cancers in less accessible locations.

Another exciting facet of this technology is its modularity. The principle of photoswitchable degradation is not limited to glucocorticoid receptors but can be adapted to target other clinically relevant receptors implicated in hormone-driven cancers. Potential targets include the oestrogen receptor, crucial in many breast cancers, and the androgen receptor, significant in prostate cancer progression. By customising the binding subunit, this approach can be tailored to a broad range of cancer types, offering a versatile platform to disrupt tumour survival pathways selectively.

Beyond direct therapeutic applications, the photoswitchable degrader system holds tremendous promise as a research tool to unravel complex signalling pathways within cancer biology. The reversible and precise control it offers over receptor presence and activity enables researchers to dissect the timing and influence of hormonal signalling on tumour behaviour without permanently altering the genome or protein expression. Such insights could pave the way for novel therapeutic targets and strategies in the future.

This scientific milestone underscores the power of interdisciplinary research, uniting organic chemistry, molecular biology, and photonics to engineer a sophisticated solution to a vexing clinical problem. The fusion of light-controlled molecular machines with the body’s own proteolytic systems opens new vistas in precision oncology. While further validation in living organisms remains crucial, the results so far invigorate hopes for more effective, less toxic cancer therapies that can outsmart tumour dormancy — a formidable obstacle long hindering patient recovery.

Looking ahead, the research team remains focused on refining the photoswitchable linker components to improve responsiveness and specificity. Additionally, integrating this technology with established cancer drugs could enhance treatment regimens by coordinating the “waking” of dormant tumour cells followed by their targeted destruction. As experimentation progresses from cell cultures towards animal models and clinical trials, the impact of this innovative methodology may soon transform cancer care paradigms — shifting the balance decisively in favour of patients grappling with drug-resistant tumours.

In summary, this pioneering research from ETH Zurich represents a sophisticated leap in the fight against cancer dormancy. By harnessing the body’s natural protein disposal system and coupling it with a photoswitch-mediated mechanism, scientists have crafted a controllable molecular switch that selectively eliminates tumour cells’ protective hormonal receptors. This approach, characterized by its precision, reversibility, and scalability, promises to overcome significant barriers in localized cancer treatment, providing a new weapon against a stealthy survival strategy exploited by tumours worldwide.

Subject of Research: Targeted degradation of glucocorticoid receptors in tumour cells using a light-controllable molecular switch to disrupt cancer cell dormancy.

Article Title: Light-controlled disruption of cancer cell dormancy via photoswitchable stress hormone receptor degraders

Web References: DOI: 10.1073/pnas.2528760123

Keywords

Cancer dormancy, glucocorticoid receptors, photoswitchable degradation, tumour microenvironment, targeted cancer therapy, ubiquitin-proteasome system, molecular switch, light-controlled therapy, lung cancer, hormone receptor modulation, optical precision, receptor degraders

Central to the dormancy enigma is how disseminated cancer cells interact with and respond to their microenvironment. Dormancy is maintained, in part, by niche-derived signals originating from surrounding stromal cells, extracellular matrix (ECM) components, and local immune populations within secondary sites. These signals intricately modulate intracellular pathways, guiding DCCs into a reversible state of proliferative arrest. The composition and mechanical properties of the ECM, for example, provide essential biochemical and biophysical cues that influence cell cycle regulation and survival, effectively instructing cancer cells to remain dormant. Unraveling these microenvironmental niches offers critical insights into how metastatic seeds persist in hostile foreign landscapes.

Delving deeper, the epigenetic and transcriptional landscape of dormant DCCs reveals another layer of complexity. Dormancy is orchestrated by specific gene expression programmes which reinforce quiescence and resistance to apoptosis. Chromatin remodeling plays a pivotal role, dynamically reshaping the accessibility of transcriptional regulators to DNA. This chromatin plasticity endows dormant cells with the ability to swiftly transition between dormancy and proliferation in response to local cues. The review highlights recent advances in understanding how modulators such as histone modifiers and DNA methylation patterns contribute to sustaining the dormant state, signposting new molecular targets to disrupt this cellular stasis.

One of the most insidious aspects of dormant DCCs is their capacity to evade immune surveillance. Despite being foreign invaders, DCCs craft sophisticated mechanisms to avoid detection and destruction by both innate and adaptive immune cells. The immune microenvironment itself undergoes remodeling as tumors manipulate immune checkpoints, secrete immunosuppressive factors, or induce local immune tolerance, creating a sanctuary niche for dormant cells. Understanding these immune escape strategies is crucial, as it presents an opportunity to harness and reinvigorate immune responses aimed at eradicating residual disease before relapse occurs.

The biology of cancer dormancy is not confined to solid tumors alone. The review draws parallels with haematologic malignancies, where residual disease and dormant-like states similarly contribute to relapse. These shared mechanisms between distinct cancer classes underscore a more universal dormancy framework across oncology. Insights gained from liquid tumors may complement findings in solid malignancies, fostering cross-disciplinary therapeutic innovations that target dormant cancer cells systemically.

Despite these illuminating mechanistic revelations, the clinical translation of dormancy biology remains limited. Currently, reliable biomarkers that can accurately identify dormant DCCs in patients are scarce, complicating early intervention strategies. Moreover, therapeutic agents specifically designed to target dormant cells or reawaken them for eradication are in nascent stages of development. Most conventional therapies aim at proliferative tumor cells, inadvertently sparing dormant populations. Addressing these translational gaps is imperative to shift the paradigm in metastasis management.

The review underscores the need for multifaceted therapeutic approaches that combine microenvironmental modulation, epigenetic reprogramming, and immunotherapeutic strategies. By disrupting signals that maintain dormancy or stimulating immune-mediated clearance, it may be possible to prevent metastatic recurrence effectively. Carefully timed treatments that target dormant cells before they re-enter the cell cycle could transform metastatic cancer from an incurable condition into a manageable or even eradicable disease state.

This evolving understanding of cancer dormancy challenges longstanding dogmas that equate metastasis solely with overt tumor expansion. Instead, it paints a more nuanced picture of dynamic cancer cell states involving periods of silence followed by aggressive resurgence. The heterogeneity of dormancy programs across cancer types and individual patients further complicates therapeutic targeting but simultaneously invites precision medicine approaches tailored to specific dormancy signatures.

An additional dimension of dormancy arises from the interplay between cancer cells and systemic factors such as inflammation, stress responses, and aging-related changes. These systemic cues can trigger dormant cells to exit quiescence, highlighting the importance of holistic patient management. Integrating dormancy biology with emerging cancer omics datasets may yield predictive models for monitoring relapse risk and guiding therapeutic decisions.

Ultimately, leveraging dormancy biology to improve patient outcomes requires concerted interdisciplinary collaboration, encompassing basic molecular research, translational studies, and clinical trials. The review by Aguirre-Ghiso and colleagues provides a roadmap for such efforts, emphasizing both the challenges and the tantalizing opportunities that dormancy-targeted interventions offer. Advancing this frontier holds promise to mitigate cancer relapse, a major obstacle that has long thwarted curative cancer therapy.

In summary, targeting the “sleeping threat” of dormant disseminated cancer cells represents a critical frontier in metastasis research. The integration of microenvironmental cues, epigenetic mechanisms, immune evasion strategies, and systemic influences forms a complex but actionable framework for therapeutic innovation. As emerging technologies enable ever deeper exploration of these dormant states, the prospect of preventing metastatic recurrence and ultimately improving survival inches closer to reality. The work synthesized in this landmark review galvanizes efforts to transform our understanding of dormancy from a biological curiosity into a cornerstone of metastasis therapy.

The stakes could not be higher: millions of cancer patients worldwide face relentless metastatic progression despite initial remission. Dormancy biology offers a paradigm shift—viewing metastasis not as an immediate and inevitable outgrowth but as a staged and potentially controllable process. By decoding the molecular language of dormancy and crafting therapies that awaken or eliminate stealthy cancer cells, the future of cancer treatment may finally turn the tide on metastatic disease.

This comprehensive review firmly establishes dormancy as a fundamental hallmark of cancer progression with profound clinical implications. While obstacles remain, the scientific community’s growing comprehension of dormant cancer cell biology aligns with an unprecedented opportunity to redesign metastasis therapy. Dormant cells may sleep, but for researchers and clinicians alike, the time to confront their sleeping threat has arrived.

Subject of Research:
Cancer dormancy and metastatic relapse; molecular and microenvironmental mechanisms regulating disseminated cancer cell quiescence and immune evasion.

Article Title:
The sleeping threat: targeting cancer dormancy to transform metastasis therapy

Article References:
Aguirre-Ghiso, J.A., Bravo-Cordero, J.J., Guo, W. et al. The sleeping threat: targeting cancer dormancy to transform metastasis therapy. Nat Rev Cancer (2026). https://doi.org/10.1038/s41568-026-00928-w

Image Credits: AI Generated

Breast tissue is dynamic, undergoing profound transformations throughout a woman’s life. From embryonic stages through puberty and hormonal changes associated with pregnancy and lactation, breast cells transition between mesenchymal and epithelial states. The mesenchymal phase marks an early developmental stage characterized by round, highly motile, and rapidly dividing cells. In contrast, the epithelial phase represents a mature, cuboidal cell morphology with limited motility and slower proliferation. Under normal physiological conditions, cells shuttle between these states through tightly regulated mechanisms that ensure tissue homeostasis.

However, the hijacking of this natural plasticity is central to breast cancer initiation and progression. Malignancy often begins when epithelial breast cells regress, recapitulating the mesenchymal phenotype that confers enhanced migratory capacity and uncontrolled proliferation—hallmarks of cancer. Intriguingly, this same cellular plasticity facilitates the opposite transition during metastasis, allowing disseminated cancer cells to revert to a dormant epithelial-like state characterized by cell cycle arrest and metabolic quiescence. This dormant state is thought to shield cancer cells from therapies and immune surveillance, enabling them to persist quietly in distant organs for prolonged intervals.

One of the pivotal discoveries from Yarden’s laboratory focuses on the role of OVOL proteins, transcription factors instrumental in regulating the epithelial-mesenchymal axis during normal breast development. Leveraging a sophisticated three-dimensional tumor microenvironment model, combined with genetic engineering techniques, the researchers induced overexpression of OVOL1 and OVOL2 proteins in highly aggressive triple-negative breast cancer (TNBC) cells—cancers notorious for their poor prognosis and limited treatment options. Remarkably, heightened OVOL expression arrested the cellular lifecycle of these TNBC cells, enforcing dormancy and dramatically suppressing tumor growth both in vitro and in vivo in xenografted female mice.

Despite the intuitive appeal of halting tumor growth, OVOL1’s involvement in dormancy revealed a dark paradox. The team found that breast tissues of cancer patients frequently harbor elevated OVOL1 levels, suggesting a dual role for this protein. In the short term, OVOL1 suppresses proliferation, acting as a brake on malignancy. Over the long term, however, elevated OVOL1 facilitates cancer cell survival by enabling the dormancy program, allowing cells to evade detection and persist in the body. When environmental or hormonal changes trigger a decline in OVOL1 expression, dormant cells abruptly resume proliferation, often displaying heightened aggressiveness.

Further interrogation of the molecular controls governing OVOL expression uncovered critical regulatory influences of growth factors and steroid hormones. Specifically, the study revealed that certain growth factors promote OVOL1 synthesis, reinforcing dormancy, whereas estrogen—through its receptor pathway—suppresses OVOL1 expression. This interaction elucidates clinical observations correlating low estrogen receptor levels and elevated OVOL1 with worse prognoses, particularly in TNBC patients. These findings implicate hormonal milieu shifts, such as those occurring during menopause or weight gain, in modulating dormancy dynamics and recurrence risk.

The tantalizing implications extend to observed epidemiological patterns. Postmenopausal fat tissue becomes a significant source of estrogen production, potentially lowering OVOL1 levels systemically and thus awakening dormant tumor cells. This novel link may transform clinical management strategies for survivors by spotlighting weight management and hormone modulation as preventive measures against relapse. Prof. Yarden emphasizes the need for future animal and human studies to validate these hypotheses and develop targeted interventions that could block dormancy onset or tumor resurgence.

Central to the study’s groundbreaking contribution is its elucidation of the biochemical cascade triggered by OVOL1-induced dormancy. The research team identified an unexpected accumulation of reactive oxygen species—primarily free radicals—within dormant cancer cells. These unstable molecules induce extensive oxidative damage, disrupting DNA integrity and stalling the cell cycle, thereby enforcing the dormant state. Significantly, prior to this report, the involvement of oxidative stress in cancer cell dormancy had not been described, marking a paradigm shift in the understanding of tumor biology.

Continuing their investigation in collaboration with Prof. Emeritus Yosef Shiloh at Tel Aviv University, the researchers uncovered profound genomic consequences of sustained oxidative stress during dormancy. The delicate balance of nuclear proteins responsible for DNA repair becomes disrupted by oxidation, compromising the function of three critical repair factors. As a result, dormant cells accumulate a substantial mutational burden during their quiescent phase, an insight that challenges the classical notion of dormancy as mere cellular suspension and depicts it as an active phase of genetic evolution.

This accumulation of mutations appears to underlie the phenomenon of aggressive relapse after dormancy. When dormant cancer cells re-enter the cell cycle, their altered genome equips them with enhanced survival capabilities and resistance to conventional therapies. These findings may partly explain why recurrent breast tumors often defy standard treatment regimens and harbor more malignant traits compared to their primary counterparts.

Prof. Yarden calls attention to the translational potential of these discoveries, noting that dormancy is not unique to breast cancer but is a feature shared by many malignancies such as prostate and melanoma. By dissecting the molecular and biochemical underpinnings of dormancy, this research opens new avenues for intercepting cancer progression by either preventing dormancy induction or forestalling the reawakening of latent tumor cells. This strategical pivot could revolutionize cancer therapeutics by addressing one of the primary sources of treatment failure and mortality.

In conclusion, the intricate dance between epithelial and mesenchymal states in breast cancer cells, orchestrated by OVOL proteins and modulated by hormonal and oxidative forces, emerges as a critical determinant of cancer dormancy and relapse. The recognition that dormant cells accumulate DNA damage and evolve during their quiescent phase recasts dormancy as a dynamic, high-stakes biological state rather than a simple pause. These revelations not only deepen our grasp of tumor biology but also herald a future where managing dormancy could translate into prolonged remission and enhanced survival for breast cancer patients worldwide.

Subject of Research: Mechanisms of breast cancer cell dormancy and relapse with a focus on OVOL proteins, oxidative stress, and hormonal regulation.

Article Title: Re-epithelialization of cancer cells increases autophagy and DNA damage: Implications for breast cancer dormancy and relapse

News Publication Date: 22-Apr-2025

Web References:
Science Signaling DOI 10.1126/scisignal.ado3473

Keywords: Breast cancer, tumor tissue, discovery research, cellular proteins, mutant proteins, cellular processes, cancer research, breast cancer cells